CTXR — Citius Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Citius Pharma Receives U.S. FDA Guidance For Planned Resubmission Of BLA For Lymphir
Citius Pharma up on plans to resubmit marketing application for cancer drug
Citius Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Says Receives Response Letter From US FDA For Lymphir For The Treatment Of Patients With Relapsed Or Refractory Cutaneous T-Cell Lymphoma
Brief: Citius Pharmaceuticals To Be Added To Russell 3000® And Russell 2000® Indexes
Brief: Citius Pharmaceuticals Announces Positive Results From The Phase 2B Study Of Halo-Lido For The Treatment Of Hemorrhoids
Citius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Citius Pharmaceuticals Inc. Reports Fiscal Second Quarter 2023 Financial Results
Citius Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals Advances Mino-Lok Phase 3 Trial Achieving 85 Of 92 Events To Date
U.S. STOCKS ON THE MOVE-Baker Hughes, Cano Health, Ascendis
Citius rises on patient enrollment for study of hemorrhoids treatment
Brief: Citius Pharmaceuticals Advances Efforts To Spin Off Oncology Asset
Brief: Citius Pharmaceuticals Confirms No Exposure To Silicon Valley Bank
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results And Provides Business Update
Citius Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Citius Pharmaceuticals Reports Fiscal Full Year 2022 Financial Results
Citius Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Citius Pharmaceuticals, Inc. Announces U.S. Food And Drug Administration Acceptance Of Biologics License Application Of Denileukin Diftitox For The Treatment Of Patients With Persistent Or Recurrent Cutaneous T-Cell Lymphoma